Results 91 to 96 of about 392 (96)

Cerliponase alfa and neuronal ceroid lipofuscinosis type 2: long-term outcomes and lessons for future research

The Lancet Neurology
openaire   +2 more sources

Serial brain MRI volumetrics and DTI analysis in atypical CLN2 patients treated with ICV cerliponase alfa

Molecular Genetics and Metabolism
Sumiko Abe, Harriet Chang, Audrey Kao, Maija Steenari, Raymond Y. Wang   +4 more
openaire   +1 more source

Serial brain MRI volumetrics and tractography of atypical CLN2 patients receiving ICV cerliponase alfa treatment

Molecular Genetics and Metabolism
Audrey Kao, Harriet Chang, Igor Nestrasil, Raymond Y. Wang   +3 more
openaire   +1 more source

Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study

Lancet Neurology, The
Peter Slasor
exaly  

New Drug: Cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease

Australian Prescriber, 2019
exaly  

Cerliponase Alfa for the Treatment of CLN2 Disease in a Patient Cohort Including Children under 3 Years

Neuropediatrics
exaly